Suche
Mein Konto
The top 20 stocks on which hedge funds bet the most: These unknown stocks offer the greatest potential!
Find out which unknown stocks hedge funds are betting on now and why they are so promising! 📈 #Investing #StockMarket
The top 20 stocks on which hedge funds bet the most: These unknown stocks offer the greatest potential!
Hedge fund professionals bet the most on these stocks
It is well known that hedge funds like to bet on unknown stocks and want to make money away from the noise on Wall Street. According to an analysis by Bank of America, it turns out that the top 20 positions of professional investors in the S&P500 are all from the second and third rows.
There is neither Apple nor Nvidia in the list, but completely different titles. These were determined based on the net weighting of Bank of America. The latter indicates the long exposure of the hedge funds minus the short exposure of the hedge funds for the individual stocks. According to February data, institutional investors are betting the most on these stocks:
Incyte – Net Hedge Fund Weighting: 40.63
Bath & Body Works Inc - Hedge Fund Net Weighting: 30.59
Invesco Ltd – Hedge Fund Net Weighting: 17.24
Universal Health Services Net Hedge Fund Weighting: 16.72
Western Digital – Net Hedge Fund Weighting: 15.95
Expedia Inc – Hedge Fund Net Weighting: 15.86
Lamb Weston Holdings Inc - Hedge Fund Net Weighting: 15.17
Qorvo Inc - Hedge Fund Net Weighting: 13.98
NiSource Inc – Hedge Fund Net Weighting: 13.76
TransDigm Group Inc - Net Hedge Fund Weighting: 12.44
Caesars Entertainment Inc - Hedge Fund Net Weighting: 11.88
Pioneer Natural Resources - Hedge Fund Net Weighting: 10.85
Hess – hedge fund net weighting: 10.55
Nasdaq Inc – Hedge Fund Net Weighting: 10.44
Dollar Tree Inc - Hedge Fund Net Weighting: 10.41
Everest Group – Hedge Fund Net Weighting: 10.29
PTC Inc - Net Hedge Fund Weighting: 10.21
Hilton Worldwide Holdings Inc - Net Hedge Fund Weighting: 9.98
Bio-Rad Laboratories - Net Hedge Fund Weighting: 9.58
VeriSign Inc – Hedge Fund Net Weighting: 9.44
It is particularly worth taking a look at the biotechnology company Incyte with a market capitalization of 12.7 billion US dollars. It's not just the hedge funds that are optimistic about a price increase - analysts see an average of 34 percent upside potential for the paper.
Market observers are similarly optimistic about Bio-Rad Laboratories, a company from the pharmaceutical sector with a particular focus on diagnostic solutions for customers. Wall Street sees an average price potential of 28.4 percent here.
If you like things a little more conservative, you can take a look at Invesco shares, for example. The asset manager is visually attractively valued with a P/E ratio of 9.8 and also offers a dividend yield of 4.8 percent. The Wall Street consensus also sees 7.6 percent upside potential for the value.